Denis Smith
AbbVie (United States)(US)Centre Hospitalier Universitaire de Bordeaux(FR)Hôpital Saint-André(FR)Hôpital Cardiologique du Haut-Lévêque(FR)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Neuroendocrine Tumor Research Advances, Genetic factors in colorectal cancer, Hepatocellular Carcinoma Treatment and Prognosis
Most-Cited Works
- → Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer(2020)2,821 cited
- → Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors(2011)2,525 cited
- → Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study(2022)842 cited
- → Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial(2020)244 cited
- → Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial(2021)213 cited
- → Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.